Tuesday, November 13, 2012
Its main competition is seeking approval of a treatment for the lung disease COPD, but the leaders of Pearl Therapeutics Inc., and investors who just ponied up $65 million to push the company’s own COPD drug into Phase III trials, are unbowed.
Monday, November 12, 2012
|Dr. Tony Fauci.|
|Patrizia Fanara and David Fineman of KineMed.|
Wednesday, November 7, 2012
Tuesday, November 6, 2012
Monday, November 5, 2012
Cancer drug maker Pharmacyclics Inc.’s stock dropped almost 20 percent at one point Monday, after it released disappointing trial data.
Pharmacyclics announced that a group of multiple myeloma patients it was testing its drug on did not experience tumor shrinkage. According to the Associated Press, the company will now try testing it in higher doses and in combination with other drugs.
|Pharmacyclics CEO Robert Duggan and CEO Maky Zanganeh.|
|BioMarin CEO Jean-Jacques Bienaime.|
Friday, November 2, 2012
|BNBuilders' David Becker (left) and Sean Truesdale.|
|Genentech co-founder Herb Boyer.|
Box checked, move on to other things and the phrase quietly floats away.